A brief history of calcitonin

Colman, Eric; Hedin, Randy; Swann, Joslyn; Orloff, David G.

doi:10.1016/s0140-6736(02)07949-7

Cited by 25 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1A ) 18 . Originally, hCT was used to treat osteoporosis and Paget’s disease 19 20 , however, due to its high intrinsic tendency to aggregate and the low bioactivity as the result of aggregation, the clinical application of hCT has been discontinued by FDA 21 22 . Moreover, amyloid deposits of hCT have been discovered in patients with medullary carcinoma of the thyroid (MTC), indicating an association between MTC and hCT aggregation 23 24 .…”

mentioning

confidence: 99%

Inhibitory effects of magnolol and honokiol on human calcitonin aggregation

Guo

Zhao

et al. 2015

Sci Rep

View full text Add to dashboard Cite

Amyloid formation is associated with multiple amyloidosis diseases. Human calcitonin (hCT) is a typical amyloidogenic peptide, its aggregation is associated with medullary carcinoma of the thyroid (MTC), and also limits its clinical application. Magnolia officinalis is a traditional Chinese herbal medicine; its two major polyphenol components, magnolol (Mag) and honokiol (Hon), have displayed multiple functions. Polyphenols like flavonoids and their derivatives have been extensively studied as amyloid inhibitors. However, the anti-amyloidogenic property of a biphenyl backbone containing polyphenols such as Mag and Hon has not been reported. In this study, these two compounds were tested for their effects on hCT aggregation. We found that Mag and Hon both inhibited the amyloid formation of hCT, whereas Mag showed a stronger inhibitory effect; moreover, they both dose-dependently disassembled preformed hCT aggregates. Further immuno-dot blot and dynamic light scattering studies suggested Mag and Hon suppressed the aggregation of hCT both at the oligomerization and the fibrillation stages, while MTT-based and dye-leakage assays demonstrated that Mag and Hon effectively reduced cytotoxicity caused by hCT aggregates. Furthermore, isothermal titration calorimetry indicated Mag and Hon both interact with hCT. Together, our study suggested a potential anti-amyloidogenic property of these two compounds and their structure related derivatives.

show abstract

mentioning

confidence: 99%

Inhibitory effects of magnolol and honokiol on human calcitonin aggregation

Guo

Zhao

et al. 2015

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In 1984, injectable salmon calcitonin (Calcimar), which had been approved by the FDA in the late 1970s for the treatment of Paget's disease and hypercalcemia, won approval for the treatment of patients with osteoporosis (2) . Market licensure was based primarily on the results from two 24‐month studies of about 100 men and women, with total body calcium (TBC) measured by neutron activation analysis as the primary efficacy end‐point.…”

Section: The Original Guidancementioning

confidence: 99%

“…While FDA officials were eager for data verifying that an increase in TBC was a valid surrogate for reduced fracture risk, they did not believe that the unsuccessful fracture trial justified withdrawal of the drug's osteoporosis indication, as some had suggested. For those who read the drug's labeling, it was clear that the osteoporosis indication was based on TBC data and that the Calcimar studies were not designed to detect differences in fracture rates (2) …”

Section: The Original Guidancementioning

confidence: 99%

The Food and Drug Administration's Osteoporosis Guidance Document: Past, Present, and Future

Colman

2003

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

“…The widespread use of calcitonin as a nasal spray is thus likely to be re-evaluated (26). Evolving therapies, including newer bisphosphonates, have impinged and would continue to impinge upon calcitonin's success as an antiosteoporosis therapeutic (Table 1).…”

Section: Figurementioning

confidence: 99%